Table 1 Completed clinical trials of targeted therapies combine with radiotherapy in HER2 + BCBM patients

NCT

00470847

Lapatinib: orally, 750 mg twice on day one followed by 1000 mg, 1250 mg, or 1500 mg once daily

WBRT: 37.5 Gy, 15 fractions, began 1–8 days after starting lapatinib

Following WBRT, patients received trastuzumab intravenously 2 mg/kg weekly and lapatinib 1000 mg orally once daily

35

I

CNS-ORR was 79%

NCT

02135159

T-DM1:

T-DM1 concomitant with RT (injection day 1, 22);

T-DM1 during and after RT [sequential RT (start day 1) followed by T-DM1 (injection day 15, 36)];

RT before T-DM1 [sequential RT (start day 1) followed by T-DM1 (injection day 22, 43)];

T-DM1 before RT [T-DM1 (First injection day 1) followed by sequential and concomitant RT (start day 18), second injection T-DM1 day 22]

WBRT

Not applicable

36

I

Not applicable

NCT

01363986

Herceptin (trastuzumab): initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks

WBRT

Not applicable

3

II

Not applicable

NCT

02563925

Tremelimumab: administered every 28 days

WBRT or SRS

Durvalumab

28

Not applicable

Not applicable

NCT

01613482

Trastuzumab: weekly, 2 mg/kg of corporal weight

Cerebral prophylactic radiation: 24 Gy, 12 fractions of 2 Gy

Not applicable

13

III

Not applicable